REDWOOD CITY, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United States Food and Drug Administration (“FDA”)…Original Article
FDA Approves Yusimry (adalimumab-aqvh), a Biosimilar to Humira
